NP_115903.1
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
microtubule-associated proteins 1A/1B light chain 3A isoform a
NCBI Official Synonym Full Names
microtubule-associated protein 1 light chain 3 alpha
NCBI Official Synonym Symbols
LC3; LC3A; ATG8E; MAP1ALC3; MAP1BLC3 [Similar Products]
NCBI Protein Information
microtubule-associated proteins 1A/1B light chain 3A
UniProt Protein Name
Microtubule-associated proteins 1A/1B light chain 3A
UniProt Synonym Protein Names
Autophagy-related protein LC3 A; Autophagy-related ubiquitin-like modifier LC3 A; MAP1 light chain 3-like protein 1; MAP1A/MAP1B light chain 3 A; MAP1A/MAP1B LC3 A; Microtubule-associated protein 1 light chain 3 alpha
UniProt Synonym Gene Names
UniProt Entry Name
MLP3A_HUMAN
NCBI Summary for MAP1LC3A
MAP1A and MAP1B are microtubule-associated proteins which mediate the physical interactions between microtubules and components of the cytoskeleton. MAP1A and MAP1B each consist of a heavy chain subunit and multiple light chain subunits. The protein encoded by this gene is one of the light chain subunits and can associate with either MAP1A or MAP1B. Two transcript variants encoding different isoforms have been found for this gene. The expression of variant 1 is suppressed in many tumor cell lines, suggesting that may be involved in carcinogenesis. [provided by RefSeq, Feb 2012]
UniProt Comments for MAP1LC3A
LC3A: is a ubiquitin-like protein that is a constituent of the ATG8-conjugation system, one of two evolutionarily conserved phosphatidylethanolamine conjugation systems necessary for the formation of the autophagosome. The human ATG8 system includes seven ubiquitin-like light chain proteins (LCPs) that are homologs of yeast LC3: MAP1LC3A, -B, -C, GABARAP, GABARAPL1, -2, and -3. Pro-LCPs are cleaved by ATG4B to expose a C-terminal glycine residue, the cytosolic LCP-I form. The exposed C-terminus is conjugated to the head group amine of phosphatidylethanolamine (PE) through an amide bond by a sequence of ubiquitination-like reactions that involves an E1 (ATG7), an E2 (ATG3), and an E3 (a complex including ATG5, ATG12, and ATG16L). The PE-congugated form (LCP-II) is tightly associated with the autophagosomal membrane. The LCP-II forms can also be delipidated by the ATG4 proteases: most of the LCPs are delipidated and liberated from the membrane before autophagosomes fuse with lysosomes. Two isoforms of the human protein are produced by alternative splicing.
Protein type: Ubiquitin-like modifier; Vesicle; Autophagy; Microtubule-binding
Chromosomal Location of Human Ortholog: 20q11.22
Cellular Component: microtubule; extrinsic to membrane; late endosome; autophagic vacuole; cytoplasmic vesicle; cytosol
Molecular Function: protein binding; phosphatidylethanolamine binding; microtubule binding; GABA receptor binding; phospholipid binding
Biological Process: mitochondrion degradation; cellular response to nitrogen starvation; autophagic vacuole formation
Product References and Citations for anti-MAP1LC3A antibody
References for protein: 1.Tanida, I., et al., J. Biol. Chem. 279(35):36268-36276 (2004). 2.He, H., et al., J. Biol. Chem. 278(31):29278-29287 (2003). 3.Mann, S.S., et al., J. Neurosci. Res. 43(5):535-544 (1996).
References for U251 cell line: 1. Westermark B.; Pontén J.; Hugosson R. (1973)." Determinants for the establishment of permanent tissue culture lines from human gliomas". Acta Pathol Microbiol Scand A. 81:791-805. [PMID: 4359449]. 2. Pontén, J.,Westermark B. (1978)." Properties of Human Malignant Glioma Cells in Vitro". Medical Biology 56: 184-193.[PMID: 359950]. 3. Geng Y.;Kohli L.; Klocke B.J.; Roth K.A.(2010). "Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent". Neuro Oncol. 12(5): 473-481.[ PMID: 20406898].
Research Articles on MAP1LC3A
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-MAP1LC3A antibody
Pathways associated with anti-MAP1LC3A antibody
Diseases associated with anti-MAP1LC3A antibody
Organs/Tissues associated with anti-MAP1LC3A antibody
|